The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications
Abstract
The peroxisome proliferator-activated receptors (PPAR-α, PPAR-β/δ, and PPAR-γ) are members of the nuclear receptor super-family, acting as ligand-inducible transcription factors and play crucial roles in glucose and lipid metabolism. These are a well-known receptor for diabetic therapy, not only influence the cardiovascular systems but are also expressed in many human solid tumors. For atherosclerosis, inflammation, and hypertension, the PPARs are considered as important therapeutic targets. Furthermore, it has been suggested that careful designing of partial agonists for PPARs, may show improvement with the side effects and also increase the therapeutic value for different diseases as cancer, inflammation and cardiovascular etc. This review summaries structural features of PPAR receptors, illustrates the method of PPAR modulator design, then analyzes recent dual- and pan-agonist with different therapeutic outcomes of the receptor to be used as a target for drugs in future. The advances in PPARs antagonists, their classification and structure-activity relationship are also summarized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956
Lehrke, M., & Lazar, M. A. (2005) · Cell · doi:10.1016/j.cell.2005.11.026 · Cited by 1,443
Oral Antidiabetic Agents: Current Role in Type 2 Diabetes Mellitus
Krentz, A. J., & Bailey, C. J. (2005) · Drugs · doi:10.2165/00003495-200565030-00005 · Cited by 1,108
Grygiel-Górniak, B. (2014) · Nutrition Journal · doi:10.1186/1475-2891-13-17 · Cited by 1,079
Oliver, W. R., Shenk, J. L., Snaith, M. R., Russell, C. S., Plunket, K. D., Bodkin, N. L., Lewis, M. C., Winegar, D. A., Sznaidman, M. L., Lambert, M. H., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091021198 · Cited by 1,046
Tyagi, S., Gupta, P., Saini, A., Kaushal, C., & Sharma, S. (2011) · Journal of Advanced Pharmaceutical Technology & Research · doi:10.4103/2231-4040.90879 · Cited by 1,017
Thomas, N., K, S., & Kapoor, N. (2016) · A Practical Guide to Diabetes Mellitus · doi:10.5005/jp/books/12651_7 · Cited by 943
Tugwood, J. D., Issemann, I., Anderson, R. G., Bundell, K. R., McPheat, W. L., & Green, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05072.x · Cited by 895
Structure of the intact PPAR-γ–RXR-α nuclear receptor complex on DNA
Chandra, V., Huang, P., Hamuro, Y., Raghuram, S., Wang, Y., Burris, T. P., & Rastinejad, F. (2008) · Nature · doi:10.1038/nature07413 · Cited by 808
Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta
Lim, H., Gupta, R. A., Ma, W.-G., Paria, B. C., Moller, D. E., Morrow, J. D., DuBois, R. N., Trzaskos, J. M., & Dey, S. K. (1999) · Genes & Development · doi:10.1101/gad.13.12.1561 · Cited by 587
PPARs and molecular mechanisms of transrepression
Ricote, M., & Glass, C. K. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.013 · Cited by 570
Leesnitzer, L. M., Parks, D. J., Bledsoe, R. K., Cobb, J. E., Collins, J. L., Consler, T. G., Davis, R. G., Hull-Ryde, E. A., Lenhard, J. M., Patel, L., et al. (2002) · Biochemistry · doi:10.1021/bi0159581 · Cited by 566
Regulation of adipocytokines and insulin resistance
Fasshauer, M., & Paschke, R. (2003) · Diabetologia · doi:10.1007/s00125-003-1228-z · Cited by 545
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
Lever, A. F., Hole, D. J., Gillis, C. R., McCallum, I. R., McInnes, G. T., MacKinnon, P. L., Meredith, P. A., Murray, L. S., Reid, J. L., & Robertson, J. W. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03228-0 · Cited by 545
Xu, H. E., Lambert, M. H., Montana, V. G., Plunket, K. D., Moore, L. B., Collins, J. L., Oplinger, J. A., Kliewer, S. A., Gampe, R. T., McKee, D. D., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241410198 · Cited by 538
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention
Peters, J. M., Shah, Y. M., & Gonzalez, F. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3214 · Cited by 492
Barbier, O., Torra, I. P., Duguay, Y., Blanquart, C., Fruchart, J.-C., Glineur, C., & Staels, B. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000015598.86369.04 · Cited by 416
Mechanism of the nuclear receptor molecular switch
NAGY, L. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.04.006 · Cited by 410
Retinoid X Receptor Heterodimers in the Metabolic Syndrome
Shulman, A. I., & Mangelsdorf, D. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043590 · Cited by 380
Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases
Monsalve, F. A., Pyarasani, R. D., Delgado-Lopez, F., & Moore-Carrasco, R. (2013) · Mediators of Inflammation · doi:10.1155/2013/549627 · Cited by 354
Peroxisome Proliferator–Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets
Brown, J. D., & Plutzky, J. (2007) · Circulation · doi:10.1161/circulationaha.104.475673 · Cited by 340
Lee, G., Elwood, F., McNally, J., Weiszmann, J., Lindstrom, M., Amaral, K., Nakamura, M., Miao, S., Cao, P., Learned, R. M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200743200 · Cited by 319
The Pathophysiology of Cardiovascular Disease and Diabetes: Beyond Blood Pressure and Lipids
Dokken, B. B. (2008) · Diabetes Spectrum · doi:10.2337/diaspect.21.3.160 · Cited by 299
Regulation of Lipid and Lipoprotein Metabolism by PPAR Activators
Gervois, P., Torra, I. P., Fruchart, J.-C., & Staels, B. (2000) · cclm · doi:10.1515/cclm.2000.002 · Cited by 249
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
Tenenbaum, A., Motro, M., & Fisman, E. Z. (2005) · Cardiovascular Diabetology · doi:10.1186/1475-2840-4-14 · Cited by 246
Novel Strategies to Improve the Anticancer Action of 5-Fluorouracil by Using Drug Delivery Systems
Arias, J. L. (2008) · Molecules · doi:10.3390/molecules13102340 · Cited by 233
Tachibana, K., Yamasaki, D., Ishimoto, K., & Doi, T. (2008) · PPAR Research · doi:10.1155/2008/102737 · Cited by 223
Review of the Structural and Dynamic Mechanisms of PPAR γ Partial Agonism
Kroker, A. J., & Bruning, J. B. (2015) · PPAR Research · doi:10.1155/2015/816856 · Cited by 217
Rieusset, J., Touri, F., Michalik, L., Escher, P., Desvergne, B., Niesor, E., & Wahli, W. (2002) · Molecular Endocrinology · doi:10.1210/me.2002-0036 · Cited by 214
PPARs and the Cardiovascular System
Hamblin, M., Chang, L., Fan, Y., Zhang, J., & Chen, Y. E. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2280 · Cited by 207
Osumi, T., Wen, J.-K., & Hashimoto, T. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)91645-s · Cited by 196
Seargent, J. M., Yates, E. A., & Gill, J. H. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705973 · Cited by 192
Stephen, R. L., Gustafsson, M. C. U., Jarvis, M., Tatoud, R., Marshall, B. R., Knight, D., Ehrenborg, E., Harris, A. L., Wolf, C. R., & Palmer, C. N. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2760 · Cited by 181
Decara, J., Rivera, P., López-Gambero, A. J., Serrano, A., Pavón, F. J., Baixeras, E., Rodríguez de Fonseca, F., & Suárez, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00730 · Cited by 180
Yessoufou, A., & Wahli, W. (2010) · Swiss Medical Weekly · doi:10.4414/smw.2010.13071 · Cited by 179
Asati, V., Mahapatra, D. K., & Bharti, S. K. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.025 · Cited by 165
Prospects for prevention and treatment of cancer with selective PPARγ modulators (SPARMs)
Sporn, M. B., Suh, N., & Mangelsdorf, D. J. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02100-1 · Cited by 159
Hsueh, W. A., & Law, R. E. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00610-6 · Cited by 148
Thiazolidinediones as anti-cancer agents.
Blanquicett, C., Roman, J., & Hart, C. M. (2008) · PubMed · Cited by 146
Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) and Neurodegenerative Disorders
Chen, Y., Wu, J., Tsai, H.-D., Huang, C., Chen, J.-J., Sun, G. Y., & Lin, T. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8259-8 · Cited by 144
Wei, D., Jiang, X., Zhou, L., Chen, J., Chen, Z., He, C., Yang, K., Liu, Y., Pei, J., & Lai, L. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8010096 · Cited by 143
Sertznig, P., Seifert, M., Tilgen, W., & Reichrath, J. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.20998 · Cited by 138
Williams, J., Borgo, S., Hasan, I., Castillo, E., Traganos, F., & Rigas, B. (2001) · PubMed · Cited by 137
Nissen, S. E., Nicholls, S. J., Wolski, K., Howey, D. C., McErlean, E. S., Wang, M.-D., Gomez, E. V., & Russo, J. (2007) · JAMA · doi:10.1001/jama.297.12.1362 · Cited by 133
Chadha, N., Bahia, M. S., Kaur, M., & Silakari, O. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.03.071 · Cited by 132
PPARγ and its ligands: therapeutic implications in cardiovascular disease
Villacorta, L., Schopfer, F. J., Zhang, J., Freeman, B. Α., & Chen, Y. (2009) · Clinical Science · doi:10.1042/cs20080195 · Cited by 118
Ebdrup, S., Pettersson, I., Rasmussen, H. B., Deussen, H.-J., Jensen, A. F., Mortensen, S. B., Fleckner, J., Pridal, L., Nygaard, L., & Sauerberg, P. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021027r · Cited by 117
Selective Modulators of PPAR- γ Activity: Molecular Aspects Related to Obesity and Side-Effects
Zhang, F., Lavan, B. E., & Gregoire, F. M. (2007) · PPAR Research · doi:10.1155/2007/32696 · Cited by 117
Han, S., Sidell, N., Fisher, P. B., & Roman, J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0985 · Cited by 113
Chinetti, G., Fruchart, J., & Staels, B. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.11.004 · Cited by 112
Captopril: a free radical scavenger.
Chopra, M., Scott, N., McMurray, J. J. V., McLay, J., Bridges, A., Smith, W. E., & Belch, J. J. F. (1989) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1989.tb05384.x · Cited by 108
Post-Transplantation Proteinuria and Sirolimus
Izzedine, H., Brochériou, I., & Francès, C. (2005) · New England Journal of Medicine · doi:10.1056/nejm200511103531922 · Cited by 107
Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode
Capelli, D., Cerchia, C., Montanari, R., Loiodice, F., Tortorella, P., Laghezza, A., Cervoni, L., Pochetti, G., & Lavecchia, A. (2016) · Scientific Reports · doi:10.1038/srep34792 · Cited by 104
The Role of PPARγ in Cardiovascular Diseases
Kvandová, M., Majzúnová, M., & Dovinová, I. (2016) · Physiological Research · doi:10.33549/physiolres.933439 · Cited by 103
Thangavel, N., Bratty, M. A., Javed, S. A., Ahsan, W., & Alhazmi, H. A. (2017) · International Journal of Medicinal Chemistry · doi:10.1155/2017/1069718 · Cited by 101
Läutamaki, R., Airaksinen, J. K. E., Seppänen, M., Toikka, J., Luotolahti, M., Ball, E., Borra, R., Härkönen, R., Iozzo, P., Stewart, M. W., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.9.2787 · Cited by 98
Allen, T. L., Zhang, F., Moodie, S. A., Clemens, L. E., Smith, A. G., Gregoire, F. M., Bell, A., Muscat, G. E. O., & Gustafson, T. A. (2006) · Diabetes · doi:10.2337/db06-0618 · Cited by 97
García-Vallvé, S., Guasch, L., Tomas‐Hernández, S., Bas-Prior, J. M. D., Ollendorff, V., Arola, L., Pujadas, G., & Mulero, M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501155f · Cited by 93
Therapeutic potential of thiazolidinediones as anticancer agents
Panigrahy, D., Shen, L. Q., Kieran, M. W., & Kaipainen, A. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.12.1925 · Cited by 92
Sun, H., Zhu, X., Cai, W., & Qiu, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040844 · Cited by 88
Energy Restriction as an Antitumor Target of Thiazolidinediones
Wei, S., Kulp, S. K., & Chen, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.065466 · Cited by 87
Sheu, S., Kaya, T., Waxman, D. J., & Vajda, S. (2004) · Biochemistry · doi:10.1021/bi048032c · Cited by 87
Diclofenac Antagonizes Peroxisome Proliferator-Activated Receptor-γ Signaling
Adamson, D. J. A., Frew, D., Tatoud, R., Wolf, C. R., & Palmer, C. N. A. (2002) · Molecular Pharmacology · doi:10.1124/mol.61.1.7 · Cited by 85
Differentiation and growth inhibition mediated via the RXR:PPARγ heterodimer in colon cancer
Cesario, R. M., Stone, J. K., Yen, W.-C., et al. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.09.010 · Cited by 81
Yu, B.-C., Chang, C.-K., Ou, H., Cheng, K., & Cheng, J.-T. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn172 · Cited by 80
Lubet, R. A., Fischer, S. M., Steele, V. E., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23765 · Cited by 77
5-Ene-4-thiazolidinones induce apoptosis in mammalian leukemia cells
Senkiv, J., Finiuk, N. S., Kaminskyy, D. V., Havrylyuk, D., Wojtyra, M., Kril, I., Gzella, A. K., Stoika, R. S., & Lesyk, R. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.089 · Cited by 76
Pioglitazone Improves Left Ventricular Diastolic Function in Patients With Essential Hypertension
HORIO, T., Suzuki, M., SUZUKI, K., Takamisawa, I., Hiuge, A., Kamide, K., Takiuchi, S., Iwashima, Y., Kihara, S., & Funahashi, T. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2005.02.003 · Cited by 72
Ptasinska, A., Wang, S., Zhang, J., WESLEY, R. A., & Danner, R. L. (2006) · The FASEB Journal · doi:10.1096/fj.06-6822com · Cited by 69
(2004) · PubMed · Cited by 69
Kiaei, M. (2008) · PPAR Research · doi:10.1155/2008/418765 · Cited by 67
Motomura, W., Takahashi, N., Nagamine, M., Sawamukai, M., Tanno, S., Kohgo, Y., & Okumura, T. (2003) · International Journal of Cancer · doi:10.1002/ijc.11561 · Cited by 61
Schaefer, K. L., Takahashi, H., Morales, V. M., Harris, G., Barton, S., Osawa, E., Nakajima, A., & Saubermann, L. J. (2006) · International Journal of Cancer · doi:10.1002/ijc.22361 · Cited by 61
Ouyang, N., Williams, J. L., & Rigas, B. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi221 · Cited by 60
Thiazolidinediones: A 2010 Perspective
Krishnaswami, A., Ravi-Kumar, S., & Lewis, J. M. (2010) · The Permanente Journal · doi:10.7812/tpp/09-052 · Cited by 59
Taniguchi, A., Fukushima, M., Sakai, M., Tokuyama, K., Nagata, I., Fukunaga, A., Kishimoto, H., Doi, K., Yamashita, Y., Matsuura, T., et al. (2001) · Metabolism · doi:10.1053/meta.2001.21028 · Cited by 59
Kristiansen, G., Jacob, J., Buckendahl, A., Grützmann, R., Alldinger, I., Sipos, B., Klöppel, G., Bahra, M., Langrehr, J. M., Neuhaus, P., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0834 · Cited by 59
Wu, K., Yang, Y., Liu, D., Qi, Y., Zhang, C., Zhao, J., & Zhao, S. (2016) · Oncotarget · doi:10.18632/oncotarget.10067 · Cited by 55
Szychowski, K. A., Leja, M. L., Kaminskyy, D. V., Kryshchyshyn‐Dylevych, A., Binduga, U. E., Pinyazhko, O. R., Lesyk, R., Tobiasz, J., & Gmiński, J. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.071 · Cited by 55
Mohazab, R. A., Paydar, M. J., Delfan, B., & Dehpour, A. R. (2012) · Epilepsy Research · doi:10.1016/j.eplepsyres.2012.02.015 · Cited by 54
NO-Donor Phenols: A New Class of Products Endowed with Antioxidant and Vasodilator Properties
Boschi, D., Tron, G. C., Lazzarato, L., Chegaev, K. Y., Cena, C., Stilo, A. D., Giorgis, M., Bertinaria, M., Fruttero, R., & Gasco, A. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0510530 · Cited by 54
Mateu, A., Ramudo, L., Manso, M. A., & DIOS, I. D. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.10.022 · Cited by 51
Preclinical Studies of a Specific PPARγ Modulator in the Control of Skin Inflammation
Mastrofrancesco, A., Kovacs, D., Sarra, M., Bastonini, E., Cardinali, G., Aspite, N., Camera, E., Chavatte, P., Desreumaux, P., Monteleone, G., et al. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.448 · Cited by 49
Mitochondria, PPARs, and Cancer: Is Receptor‐Independent Action of PPAR Agonists a Key?
Scatena, R., Bottoni, P., & Giardina, B. (2008) · PPAR Research · doi:10.1155/2008/256251 · Cited by 46
Cardiac dysfunction in adipose triglyceride lipase deficiency: treatment with a PPARα agonist
Wölkart, G., Schrammel, A., Dörffel, K., Haemmerle, G., Zechner, R., & Mayer, B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01490.x · Cited by 44
Ye, F., Zhang, Z., Luo, H., Shen, J., Chen, K., Shen, X., & Jiang, H. (2005) · ChemBioChem · doi:10.1002/cbic.200500186 · Cited by 44
Identification of a New Type of Covalent PPARγ Agonist using a Ligand-Linking Strategy
Ohtera, A., Miyamae, Y., Yoshida, K., Maejima, K., Akita, T., Kakizuka, A., Irie, K., Masuda, S., Kambe, T., & Nagao, M. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00628 · Cited by 44
Dual Acting and Pan-PPAR Activators as Potential Anti-diabetic Therapies
Heald, M., & Cawthorne, M. A. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_2 · Cited by 43
Mally, P., Mishra, R., Gandhi, S., DeCastro, M., Nankova, B. B., & LaGamma, E. F. (2004) · Pediatric Research · doi:10.1203/01.pdr.0000119365.21770.45 · Cited by 42
Burgermeister, E., Friedrich, T., Hitkova, I., Regel, I., Einwächter, H., Zimmermann, W., Röcken, C., Perren, A. A., Wright, M. B., Schmid, R. M., et al. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01421-10 · Cited by 41
Matrisciano, F., & Pinna, G. (2020) · Neurobiology of Stress · doi:10.1016/j.ynstr.2020.100222 · Cited by 41
Irons, B. K., Greene, R. S., Mazzolini, T. A., Edwards, K. L., & Sleeper, R. B. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.2.168 · Cited by 39
Saha, S., Chan, D. S. Z., Lee, C. Y., Wong, W., New, L. S., Chui, W. K., Yap, C. W., Chan, E. C. Y., & Ho, H. K. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.09.021 · Cited by 38
El-Haleim, E. A. A., Bahgat, A. K., & Saleh, S. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.01.011 · Cited by 38
Schäfer, H., Linz, W., Falk, E., Glien, M., Glombik, H., Korn, M., Wendler, W., Herling, A. W., & Rütten, H. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.165 · Cited by 36
Mizuno, C. S., Chittiboyina, A. G., Shah, F., Patny, A., Kurtz, T. W., Pershadsingh, H. A., Speth, R. C., Karamyan, V. T., de Carvalho, P. B., & Avery, M. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901272d · Cited by 35
A novel PPARα agonist ameliorates insulin resistance in dogs fed a high-fat diet
Tsunoda, M., Kobayashi, N., Ide, T., Utsumi, M., Nagasawa, M., & Murakami, K. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00627.2007 · Cited by 34
Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients
Panunti, B. A., & Fonseca, V. A. (2006) · Vascular Pharmacology · doi:10.1016/j.vph.2005.11.013 · Cited by 32
Development of a new class of potential antiatherosclerosis agents: NO-donor antioxidants
Cena, C., Boschi, D., Tron, G. C., Chegaev, K. Y., Lazzarato, L., Stilo, A. D., Aragno, M., Fruttero, R., & Gasco, A. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.10.006 · Cited by 32
Yuan, H., Kopelovich, L., Yin, Y., Lu, J., & Glazer, R. I. (2012) · Oncotarget · doi:10.18632/oncotarget.457 · Cited by 28
Zhu, W., Yan, H. M., Li, S., Nie, W., Fan, F., & Zhu, J. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.09.028 · Cited by 28
Suzuki, S., Mori, Y., Nagano, A., Naiki‐Ito, A., Kato, H., Nagayasu, Y., Kobayashi, M., Kuno, T., & Takahashi, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122071 · Cited by 28
Partial Peroxisome Proliferator-Activated Receptor Agonist Angiotensin Receptor Blockers
Towfighi, A., & Ovbiagele, B. I. (2008) · Cerebrovascular Diseases · doi:10.1159/000139656 · Cited by 27
Cardiovascular effects of the thiazolidinediones
Qayyum, R., & Schulman, P. M. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.596 · Cited by 27
Ngala, R. A., Stocker, C. J., Roy, A. G., Hislop, D. C., Wargent, E. T., Bell, R., Hassall, D. G., Harling, J. D., Billin, A. N., Willson, T. M., et al. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01371.x · Cited by 26
PPARγ Inhibitors as Novel Tubulin‐Targeting Agents
Schaefer, K. L. (2008) · PPAR Research · doi:10.1155/2008/785405 · Cited by 25
Silva-Abreu, M., Espinoza, L. C., Rodríguez-Lagunas, M. J., Fábrega, M.-J., Espina, M., García, M. L., & Calpena, A. C. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122548 · Cited by 25
HL005—A new selective PPARγ antagonist specifically inhibits the proliferation of MCF-7
Lü, W., Che, P., Zhang, Y., Li, H., Zou, S., Zhu, J., Deng, J., Shen, X., Jiang, H., Li, J., et al. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.01.019 · Cited by 23
Fujii, D., Yoshida, K., Tanabe, K., Hihara, J., & Toge, T. (2004) · PubMed · Cited by 22
Liao, C., Liu, B., Shi, L. M., Zhou, J., & Lu, X. (2005) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2005.02.006 · Cited by 18
Novel antioxidant agents deriving from molecular combination of Vitamin C and NO-donor moieties
Cena, C., Chegaev, K. Y., Balbo, S., Lazzarato, L., Rolando, B., Giorgis, M., Marini, E., Fruttero, R., & Gasco, A. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.03.014 · Cited by 17
Leveraging Nuclear Receptors as Targets for Pathological Ocular Vascular Diseases
Yao, P., Peavey, J. J., & Malek, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082889 · Cited by 13
Rennings, A. J. M., Rüssel, F. G. M., Li, Y., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.360 · Cited by 10
Linciano, P., Filippis, B. D., Ammazzalorso, A., Amoia, P., Cilurzo, F., Fantacuzzi, M., Giampietro, L., Maccallini, C., Petit, C., & Amoroso, R. (2019) · MedChemComm · doi:10.1039/c9md00286c · Cited by 5
Cited by
The role of lipid metabolic reprogramming in tumor microenvironment
Yang, K., Wang, X., Song, C., He, Z., Wang, R., Xu, Y., Jiang, G., Wan, Y., Mei, J., & Mao, W. (2023) · Theranostics · doi:10.7150/thno.82920 · Cited by 270
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Cheng, H. S., Tan, W. R., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205055 · Cited by 264
Mechanisms Mediating the Regulation of Peroxisomal Fatty Acid Beta-Oxidation by PPARα
Tahri-Joutey, M., Andreoletti, P., Surapureddi, S., Nasser, B., Cherkaoui-Malki, M., & Latruffe, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168969 · Cited by 253
Shao, F., Wang, X., Wu, H., Wu, Q., & Zhang, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.825086 · Cited by 250
“In a wide array of neurodegenerative diseases, including AD, PD, ALS, activation of PPARγ has been found beneficially regulated by various ligands or natural substances (Mirza et al., 2019).”
BackgroundImmune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target
Chen, J., Liu, Q., He, J., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.958790 · Cited by 164
Metadata
- Authors
- Mirza, A. Z., Althagafi, I. I., & Shamshad, H.
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 166
- Pages
- 502-513
- ISSN
- 0223-5234 (ISSN-L)
- OpenAlex
- W2914645254
- Cited by
- 544
- References
- 119
- FWCI
- 15.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.